Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics reports developments tied to its oncology drug-development portfolio and corporate transition. The company had developed novel oncology therapies including ONCT-534, a dual-action androgen receptor inhibitor for relapsed or refractory metastatic castration-resistant prostate cancer; ONCT-808, an autologous ROR1-targeting CAR T therapy for aggressive B-cell lymphoma; and zilovertamab, an investigational ROR1 monoclonal antibody.
Recurring news themes include clinical-study updates, safety and efficacy data, financial results, termination of clinical programs, strategic-alternative activity, asset sales and the wind-down of operations.
Oncternal Therapeutics (Nasdaq: ONCT) will present a company overview at the Stifel Virtual Healthcare Conference on November 16, 2020, at 2:00 p.m. ET. The presentation will be led by Dr. James Breitmeyer, President and CEO. Investors can access the webcast and replay through the Events & Presentations page on the company's website. Oncternal is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for unmet medical needs. Key candidates include cirmtuzumab and TK216, targeting critical cancer pathways.
Oncternal Therapeutics (Nasdaq: ONCT) announced FDA's Rare Pediatric Disease Designation for TK216, aimed at treating Ewing sarcoma. Interim Phase 1 data showed two complete responses among 15 evaluable patients. The company raised $10.1 million in equity financing during Q3 2020, strengthening its balance sheet. Financial results revealed a net loss of $4.4 million for Q3 2020, with $0.6 million in grant revenue and total operating expenses of $5.0 million. The current funds are expected to sustain operations into Q2 2021.